Combination of CKD-702 and Irinotecan for Advanced Gastric Cancer
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET
This study is testing if a new combination of two drugs, CKD-702 and irinotecan, can help people with advanced gastric cancer who haven't responded well to previous treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | National Cancer Center, Korea Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Goyang, Gyeonggi) |
| Trial ID | NCT05750290 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of CKD-702, a bispecific antibody targeting MET and EGFR, in combination with irinotecan for patients with advanced gastric cancer who have already undergone two or more lines of chemotherapy. The study aims to determine if this combination can improve treatment outcomes for patients whose tumors overexpress either MET or EGFR. Participants will receive biweekly doses of irinotecan alongside CKD-702 to evaluate the potential benefits of this novel therapeutic approach.
Who should consider this trial
Good fit: Ideal candidates are patients with advanced gastric cancer who have failed two or more lines of chemotherapy and have tumors that overexpress MET or EGFR.
Not a fit: Patients who have previously received treatment with anti-MET or EGFR bispecific antibodies may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with advanced gastric cancer who have limited treatment alternatives.
How similar studies have performed: While the specific combination of CKD-702 and irinotecan is novel, similar approaches targeting MET and EGFR have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Failed 2 or more lines of chemotherapy * Tumor overexpressing either MET or EGFR * Measurable lesion Exclusion Criteria: * Prior treatment with anti-MET/EGFR bispecific antibody
Where this trial is running
Goyang, Gyeonggi
- National Cancer Center — Goyang, Gyeonggi, Korea, Republic of (Recruiting)
Study contacts
- Study coordinator: Hark K Kim, MD,PhD
- Email: hkim@ncc.re.kr
- Phone: +82-31-920-2238
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.